514 related articles for article (PubMed ID: 11965605)
1. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies.
Behr TM; Béhé MP
Semin Nucl Med; 2002 Apr; 32(2):97-109. PubMed ID: 11965605
[TBL] [Abstract][Full Text] [Related]
2. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
3. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors.
Behr TM; Jenner N; Béhé M; Angerstein C; Gratz S; Raue F; Becker W
J Nucl Med; 1999 Jun; 40(6):1029-44. PubMed ID: 10452322
[TBL] [Abstract][Full Text] [Related]
4. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential.
Behr TM; Béhé M; Angerstein C; Gratz S; Mach R; Hagemann L; Jenner N; Stiehler M; Frank-Raue K; Raue F; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3124s-3138s. PubMed ID: 10541353
[TBL] [Abstract][Full Text] [Related]
5. Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin.
Behr TM; Jenner N; Radetzky S; Béhe M; Gratz S; Yücekent S; Raue F; Becker W
Eur J Nucl Med; 1998 Apr; 25(4):424-30. PubMed ID: 9553173
[TBL] [Abstract][Full Text] [Related]
6. Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy.
de Jong M; Bakker WH; Bernard BF; Valkema R; Kwekkeboom DJ; Reubi JC; Srinivasan A; Schmidt M; Krenning EP
J Nucl Med; 1999 Dec; 40(12):2081-7. PubMed ID: 10616889
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic applications of radiolabeled peptides in nuclear endocrinology.
Behr TM; Béhé M; Becker W
Q J Nucl Med; 1999 Sep; 43(3):268-80. PubMed ID: 10568142
[TBL] [Abstract][Full Text] [Related]
8. Imaging tumors with peptide-based radioligands.
Behr TM; Gotthardt M; Barth A; Béhé M
Q J Nucl Med; 2001 Jun; 45(2):189-200. PubMed ID: 11476170
[TBL] [Abstract][Full Text] [Related]
9. CCK receptors in human neuroendocrine tumors: clinical implications.
Reubi JC
Scand J Clin Lab Invest Suppl; 2001; 234():101-4. PubMed ID: 11713969
[TBL] [Abstract][Full Text] [Related]
10. Two peptide receptor ligands (99m)Tc-EDDA/HYNIC-Tyr(3)-octreotide and (99m)Tc-EDDA/HYNIC-(D)Glu-octagastrin for scintigraphy of medullary thyroid carcinoma.
Kosowicz J; Mikołajczak R; Czepczyński R; Ziemnicka K; Gryczyńska M; Sowiński J
Cancer Biother Radiopharm; 2007 Oct; 22(5):613-28. PubMed ID: 17979564
[TBL] [Abstract][Full Text] [Related]
11. Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas.
Reubi JC; Waser B
Int J Cancer; 1996 Sep; 67(5):644-7. PubMed ID: 8782652
[TBL] [Abstract][Full Text] [Related]
12. Radiolabeled gastrin/CCK analogs in tumor diagnosis: towards higher stability and improved tumor targeting.
Kaloudi A; Nock BA; Krenning EP; Maina T; De Jong M
Q J Nucl Med Mol Imaging; 2015 Sep; 59(3):287-302. PubMed ID: 26158215
[TBL] [Abstract][Full Text] [Related]
13. Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives.
Béhé M; Becker W; Gotthardt M; Angerstein C; Behr TM
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1140-6. PubMed ID: 12768330
[TBL] [Abstract][Full Text] [Related]
14. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors.
Reubi JC; Schaer JC; Waser B
Cancer Res; 1997 Apr; 57(7):1377-86. PubMed ID: 9102227
[TBL] [Abstract][Full Text] [Related]
15. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W
Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695
[TBL] [Abstract][Full Text] [Related]
16. CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs.
Nock BA; Maina T; Béhé M; Nikolopoulou A; Gotthardt M; Schmitt JS; Behr TM; Mäcke HR
J Nucl Med; 2005 Oct; 46(10):1727-36. PubMed ID: 16204724
[TBL] [Abstract][Full Text] [Related]
17. [The use of a new analogue DGlu-Octagastrin in scintigraphy of medullary thyroid carcinoma].
Kosowicz J; Czepczyński R; Ziemnicka K; Gryczyńska M; Sowiński J
Endokrynol Pol; 2006; 57(4):427-30. PubMed ID: 17006848
[TBL] [Abstract][Full Text] [Related]
18. Expression of the cholecystokinin 2-receptor in normal human thyroid gland and medullary thyroid carcinoma.
Blaker M; de Weerth A; Tometten M; Schulz M; Höppner W; Arlt D; Hoang-Vu C; Dralle H; Terpe H; Jonas L; von Schrenck T
Eur J Endocrinol; 2002 Jan; 146(1):89-96. PubMed ID: 11751073
[TBL] [Abstract][Full Text] [Related]
19. Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo.
Reubi JC; Waser B; Schaer JC; Laederach U; Erion J; Srinivasan A; Schmidt MA; Bugaj JE
Eur J Nucl Med; 1998 May; 25(5):481-90. PubMed ID: 9575243
[TBL] [Abstract][Full Text] [Related]
20. Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides.
Breeman WA; Fröberg AC; de Blois E; van Gameren A; Melis M; de Jong M; Maina T; Nock BA; Erion JL; Mäcke HR; Krenning EP
Nucl Med Biol; 2008 Nov; 35(8):839-49. PubMed ID: 19026945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]